New Delhi: The Russian Direct Investment Fund (RDIF) and Gamaleya Center on Wednesday said one-shot Sputnik Light vaccine demonstrates 70 percent efficacy against infection with the Delta variant of coronavirus during the first three months after vaccination.
Gamaleya Center has submitted an article analysing the efficacy of the Sputnik Light vaccine against the Delta variant to the medRxiv preprint server for health sciences, RDIF said in a statement.
The analysis was conducted based on data from 28,000 participants who had received a single dose of Sputnik Light, compared with a control group of 5.6 million individuals who were not vaccinated. The data used in the study was collected in July 2021 in Moscow, it added.
“The vaccine is more than 75 percent effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalisations,” RDIF said in a statement.
ALSO READ | India reports 18,833 new COVID-19 cases, active count drops to lowest in nearly 7 months
The one-shot Sputnik Light vaccine is authorised in more than 15 countries, with ongoing registration processes in another 30 countries, it added.